COMP <GO>
RGEN vs IBRX // OPERATING MARGIN
Repligen Corporation (NASDAQ) VS. ImmunityBio Inc. (NASDAQ) • 15-METRIC TALLY: RGEN 8
— IBRX 3
▲ OPERATING MARGIN LEADER: RGEN
LAST: $172.95 (-2.25%) • MKT CAP: $10.03B
operating-margins
1.80%
LAST: $7.95 (-4.10%) • MKT CAP: $8.79B
operating-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGEN VS. IBRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RGEN | IBRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.20% | 96.00% | -7.80 | IBRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.30% | -27.30% | +29.60 | RGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.88% | -3.33% | +4.21 | RGEN | /fcf-yield <GO> |
| Operating Margin ACTIVE | 1.80% | -60.00% | +61.80 | RGEN | /operating-margins <GO> |
| Net Profit Margin | 1.60% | -60.00% | +61.60 | RGEN | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 180.00% | -183.30 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.31 | 0.45 | +8.86 | RGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | RGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 44.3 | +3.70 | RGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 1.05 | -0.01 | IBRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 29.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.03B | $8.79B | $1.25B | RGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RGEN REV | IBRX REV | RGEN GROSS % | IBRX GROSS % | RGEN FCF | IBRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $154.5M | $113.3M | — | 99.3% | $93.9M | -$308.8M |
| FY 2024 | $98.3M | $14.7M | — | 100.0% | $149.7M | -$398.1M |
| FY 2023 | $133.6M | $622.0K | — | — | $113.9M | -$366.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGEN // BETA 1.04
IBRX // BETA 1.05